Allogene Therapeutics Inc (ALLO) concluded trading on Wednesday at a closing price of $1.21, with 9.59 million shares of worth about $11.6 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -43.98% during that period and on July 09, 2025 the price saw a gain of about 0.83%. Currently the company’s common shares owned by public are about 218.60M shares, out of which, 149.51M shares are available for trading.
Stock saw a price change of 2.54% in past 5 days and over the past one month there was a price change of -14.79%. Year-to-date (YTD), ALLO shares are showing a performance of -42.92% which decreased to -43.19% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.86 but also hit the highest price of $3.78 during that period. The average intraday trading volume for Allogene Therapeutics Inc shares is 3.06 million. The stock is currently trading -3.97% below its 20-day simple moving average (SMA20), while that difference is down -4.55% for SMA50 and it goes to -36.74% lower than SMA200.
Allogene Therapeutics Inc (NASDAQ: ALLO) currently have 218.60M outstanding shares and institutions hold larger chunk of about 66.02% of that.
The stock has a current market capitalization of $264.66M and its 3Y-monthly beta is at 0.34. It has posted earnings per share of -$1.23 in the same period. It has Quick Ratio of 9.71 while making debt-to-equity ratio of 0.23. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALLO, volatility over the week remained 6.94% while standing at 7.21% over the month.
Analysts are in expectations that Allogene Therapeutics Inc (ALLO) stock would likely to be making an EPS of -0.26 in the current quarter, while forecast for next quarter EPS is -0.24 and it is -0.99 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.3 which is -0.21 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.32 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 23.59% while it is estimated to increase by 2.30% in next year. EPS is likely to grow at an annualized rate of 8.47% for next 5-years, compared to annual growth of 6.26% made by the stock over the past 5-years.
Coverage by Citizens JMP stated Allogene Therapeutics Inc (ALLO) stock as a Mkt outperform in their note to investors on March 14, 2025, suggesting a price target of $5 for the stock. On August 08, 2024, Oppenheimer Resumed their recommendations, while on May 31, 2024, Piper Sandler Initiated their ratings for the stock with a price target of $11. Stock get a Mkt perform rating from JMP Securities on January 05, 2024.
